4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-24-024299
Chief Business Officer sold 28,528 shares at an average $28.46 ($811,865)
- Chief Business Officer acquired 28,528 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| McNeill Jonathan Chief Business Officer | 2024-02-29 | Option exercise 10b5-1 | +4,268 | $0.73 | $3,116 | 147,886 | D |
| McNeill Jonathan Chief Business Officer | 2024-02-29 | Sale 10b5-1 | −4,268 | $27.50 | $117,370 | 143,618 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-01 | Option exercise 10b5-1 | +24,260 | $0.73 | $17,710 | 167,878 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-01 | Sale 10b5-1 | −14,103 | $28.25 | $398,410 | 153,775 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-01 | Sale 10b5-1 | −8,715 | $29.06 | $253,258 | 145,060 | D |
| McNeill Jonathan Chief Business Officer | 2024-03-01 | Sale 10b5-1 | −1,442 | $29.70 | $42,827 | 143,618 | D |
| Derivatives | |||||||
| McNeill Jonathan Chief Business Officer | 2024-02-29 | Option exercise · Stock option (right to buy) 10b5-1 | −4,268 | 24,260 | D | ||
| McNeill Jonathan Chief Business Officer | 2024-03-01 | Option exercise · Stock option (right to buy) 10b5-1 | −24,260 | 0 | D | ||
| Open-market sales · 28,528 sh · avg $28.46 · $811,865 | |||||||
Loading xslF345X05/ownership.xml…